tolebrutinib
sanofi
['tolebrutinib', '#ms ', 'sanofi', 'emergent ']
there were no observed tolebrutinib ( ) dose effects for treatment-emergent adverse events in the double-blind portion, as well as no new safety signals seen for those with #ms who crossed over in the open-label extension. #aanam 
Associate editorial director, @Neurology_Live 🧠 and @CGT_Live 🧬 Host of the #MindMoments podcast 🎧 and @medicalwrldnews Deep Dive 📺